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     Background     Sensory neuropathy (paresthesias), tinnitus, hearing impairment, and Raynaud phenomena are side effects 
of cisplatin-based chemotherapy used to treat testicular cancer patients. We assessed the long-term occur-
rence of these side effects among testicular cancer survivors according to the treatment they received.   
     Methods     A total of 1814 men who were treated for unilateral testicular cancer in Norway during 1980  –  1994 were 
invited to participate in a national multicenter follow-up survey conducted during 1998  –  2002. The men 
were allocated to six groups according to the treatment they had received. Self-reported symptoms were 
assessed by a mailed questionnaire that included the Scale for Chemotherapy-Induced Neurotoxicity. A 
total of 1409 participants who responded to the questionnaire and/or underwent audiometry were assess-
able in this study. Respondents to the questionnaire (n = 1402) scored the relevant symptoms according 
to how troubled they were by each (not at all, a little, quite a bit, or very much). Hearing impairment was 
objectively assessed by audiometry at 4000 Hz in 755 men (seven of whom did not respond to the ques-
tionnaire). Group comparisons of symptom assessments were performed with      
2   or Kruskal  –  Wallis tests. 
Associations between relevant factors and self-reported symptoms or hearing impairment measured by 
audiometry were assessed using proportional odds ordinal logistic regression models and linear regres-
sion models, respectively. All statistical tests were two-sided.   
     Results     The median follow-up for the 1409 assessable men was 10.7 years (range = 4  –  21 years). All chemotherapy 
groups had statistically significantly higher odds for increasing severity of all assessed symptoms and 
inferior audiometric results compared with men who did not receive chemotherapy. Among chemotherapy-
treated men, 39% (95% confidence interval [CI] = 35% to 43%) reported Raynaud-like phenomena (defined 
as white or cold hands or fingers [or feet or toes] on cold exposure), 29% (95% CI = 25% to 33%) reported 
paresthesias in the hands or feet, 21% (95% CI = 18% to 25%) reported hearing impairment, and 22% (95% 
CI = 19% to 26%) reported tinnitus as major symptoms troubling them quite a bit or very much. Hearing 
impairment (odds ratio [OR] = 5.3, 95% CI = 3.0 to 9.2) and tinnitus (OR = 7.1, 95% CI = 4.1 to 12.4) were 
particularly common in the dose-intensive chemotherapy group compared with the no chemotherapy 
group. Men who were treated with radiotherapy had higher odds of self-reported paresthesias in feet 
compared with those not treated with radiotherapy (OR = 1.5, 95% CI = 1.01 to 2.1,   P   = .04).   
     Conclusion     Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy were more 
often troubled by dose-dependent neurological side effects and Raynaud-like phenomena compared with 
those who were not treated with chemotherapy.   
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                                                        Testicular germ cell cancer is the most common cancer among 
20- to 40-year-old men, and the cure rate for this cancer currently 
exceeds 95% (  1  ,  2  ). Long-term side effects of treatment may there-
fore have an impact on the daily lives of testicular cancer survivors 
for several decades. 
  Sensory neuropathy, tinnitus, and hearing impairment are well-
known neurotoxic side effects of cisplatin (  3  ,  4  ), which, for three 
decades, has been the cornerstone for chemotherapeutic treatment of 
testicular cancer patients. Raynaud phenomenon  —  well-demarcated 
discoloration of the ﬁ   ngers and toes upon exposure to cold  —  is 
another common side effect following chemotherapy for testicular 
cancer (  3  ,  5  ,  6  ), and both vascular and neurological mechanisms may 
be involved in the abnormal vasoregulation that causes vasospasms of 
the digital arterioles leading to Raynaud phenomenon ( 7  ). Bleomycin, 
which is commonly a part of cisplatin-based combination regimens 
that are used to treat testicular cancer, is considered to be an impor-
tant causal factor for the development of Raynaud phenomenon (  5  ,  8  ), 
and cisplatin may also be associated with this phenomenon (  9  ). 
  In some testicular cancer patients, these side effects of che-
motherapy may decrease in severity and even disappear during the 
ﬁ  rst few years after treatment (  3  ,  10    –    13  ). In other patients, these 
side effects are long lasting and can inﬂ  uence the patient  ’  s quality 
of life, daily activities, and ability to work (  3  ,  4  ,  14  ,  15  ). Proper coun-
seling regarding the risk of long-term treatment-related side ef-
fects is an essential part of the care of cancer patients and survivors. 
High-quality long-term follow-up data are needed to guide physi-
cians in their recommendations about choice of optimal treatment 
for patients and for informing patients about lifestyle changes that 
may reduce the occurrence of some side effects. 
  Typically, the prevalence of side effects detected using ob    jective 
criteria is greater than that reported by the patients (  10  ,  11  ). There are 
several reasons for this difference. Patients may adapt to their symp-
toms over time and may therefore underreport their complaints (  16  ), 
and some toxic effects may not affect a patient’s daily life (eg, reduced 
hearing at frequencies >4000 Hz) (  10  ,  11  ). Although subjective and 
objective assessments of toxicity are important for the clinical inves-
tigator who wants to understand the etiology of side effects, the level 
of long-term self-reported toxicity probably best reﬂ  ects the effect of 
treatment on a cancer survivor’s well-being during daily life. 
  The aim of this study was to assess the occurrence of self-
reported paresthesias (sensory neuropathies), Raynaud-like phe-
nomena (white or cold hands or ﬁ  ngers [toes or feet] on exposure 
to cold), tinnitus, and impaired hearing (also measured objectively 
via audiometry at 4000 Hz) according to detailed treatment 
classiﬁ  cations in a large cohort of unselected testicular cancer sur-
vivors 4  –  21 years after treatment. In particular, we assessed the 
occurrence of these side effects following standard cisplatin-based 
chemotherapy courses (20 mg/m  2   for ﬁ  ve consecutive days) sepa-
rately from those who received more dose-intensive regimens. In a 
secondary analysis, we tested the hypothesis that these long-term 
side effects may be associated with tobacco smoking. 
    Patients and Methods 
    Population and Study Design 
  From January 4, 1998, through April 11, 2002, a national follow-up 
survey was performed to assess physical and psychological 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  The side effects of cisplatin-based chemotherapy used to treat tes-
ticular cancer patients include sensory neuropathy, tinnitus, hearing 
impairment, and Raynaud phenomena.   
    Study design 
  A cross-sectional study that assessed the long-term occurrence of 
cisplatin-associated side effects among testicular cancer survivors 
according to the treatment they received. Men who received 
chemotherapy were allocated to three groups based on cisplatin 
administration (100 mg/m 
2  cisplatin over 5 consecutive days in first 
two groups): up to four cycles, five or more cycles, or dose-intensive 
chemotherapy (100 mg/m 
2  cisplatin over 2 consecutive days or a 
total dose exceeding 100 mg/m 
2 ). Self-reported symptoms were 
assessed by a mailed questionnaire, and hearing impairment was 
objectively assessed by audiometry at 4000 Hz.   
    Contribution 
  At 4  –  21 years after the initiation of treatment for testicular cancer, 
compared with men not treated with chemotherapy, those who had 
received any chemotherapy had higher risk for increasing severity 
of all assessed symptoms and, except for those who received five 
or more cycles, statistically significantly worse audiometric results.   
    Implications 
  These findings support the current approach of using risk-specific 
recommendations in the treatment of testicular cancer to minimize 
side effects in good- and intermediate-risk patients and suggest 
that cisplatin should be administered over the course of 5 days 
rather than 2 days.   
    Limitations 
  The findings are largely based on self-reported symptoms, and the 
reported toxic effects were, with the exception of hearing threshold 
measurements, not objectively confirmed. The screening instru-
ment was brief and did not address each symptom in detail. There 
was no information about the existence of symptoms before diag-
noses or whether they changed over time. 
    From the Editors       
    
morbidity in long-term survivors of testicular cancer. All men 
who were treated for unilateral germ cell testicular cancer in 
Norway from January 1, 1980, through December 31, 1994, and 
were alive as of 1 month before invitation were identified through 
the Cancer Registry of Norway and the regional university hos-
pitals. Testicular cancer survivors aged 18  –  75 years were invited 
to participate. Following our receipt of written informed consent 
to participate, the study population received a mailed question-
naire, which included questions that assessed the relevant symp-
toms (  Table 1  ), and an appointment for a clinical examination. In 
three of the five collaborating oncology centers, the clinical ex-
amination included pure tone audiometry. Men were excluded 
from this study if they had undergone bilateral orchiectomy 
for any reason, had been diagnosed with extragonadal germ cell 
cancer or other malignancies except skin cancer, or had mental 
retardation. Further details of the study design are described 
elsewhere (  17  ).       1684   Articles | JNCI  Vol. 101, Issue 24  |  December 16, 2009
  Of the 1814 men who were invited, we included 1462 (80.6%) 
as participants (10 men were untraceable, 340 did not respond, one 
was deceased, and one withdrew from the study at a later stage). 
Most of the participants (n = 1271) answered the questionnaire and 
underwent the clinical examination, 25 participants only under-
went the clinical examination, and 166 participants only answered 
the questionnaire. The study sample in this study on Raynaud-like 
phenomena and neurological side effects consisted of 1409 partic-
ipants (78% of the men originally invited): four men were excluded 
because they had undergone cranial irradiation, 25 were excluded 
because their testicular cancers had been treated with a carboplatin-
based chemotherapy regimen without a cisplatin-based regimen, 
one was excluded because of treatment with dactinomycin only, 
and 23 were excluded because data on all symptoms that were 
assessed and audiometry were missing. 
  Primary data on all invited men regarding tumor histology 
(seminoma or nonseminoma), tumor stage according to the Royal 
Marsden Hospital staging system (  18  ), type of treatment, and his-
tory of relapse were retrieved from the patient’s medical records. 
We retrieved additional details about the chemotherapy treatment 
from the medical records of all men who participated in this study. 
This study was approved by the Committee for Medical Research 
Ethics of the Southern Health Region of Norway.   
    Standards of Treatment, 1980  –  1994 
  All men included in this study were treated either within the 
Swedish  –  Norwegian testicular cancer project (SWENOTECA 
collaboration) or according to the European Organization for 
Research and Treatment of Cancer and Medical Research Council 
protocols, as previously described (  17  ). All men in the study sample 
who were treated with chemotherapy received cisplatin (n = 528). 
The initial regimen was cisplatin in combination with vinblastine 
and bleomycin (CVB; n = 202), bleomycin and etoposide (BEP; 
n = 287), or etoposide (n = 9). Thirty men received other combina-
tions as the initial regimen. Cisplatin was usually administered at 
dose of 100 mg/m  2   over the course of 5 days per cycle. However, for 
57 men who were treated according to specific protocols, cisplatin 
was given at higher dose intensities in at least one of the adminis-
tered cycles, either at a dose that exceeded 100 mg/m  2   per cycle or 
by administering the cisplatin dose over the course of 2 days (  19    –    22  ). 
Eight patients received carboplatin-based chemotherapy regimens 
(median cumulative dose = 2975 mg, range = 1590  –  3575 mg) in 
addition to cisplatin-based regimens. Bleomycin was given as part 
of the chemotherapy treatment in 511 of the 528 chemotherapy-
treated patients and was administered as a bolus dose, mostly 
within a limited cumulative dose range (median dose = 300    000 IU, 
range = 30    000  –  540    000 IU; 77% received a cumulative dose 
between 240    000 and 360    000 IU). Vincristine was administered in 
40 of the cases at cumulative doses of 2  –  27 mg (median dose = 
7 mg). A rigorous hydration regimen was standard for all regimens. 
    Seminomas.             Most patients with early-stage seminomas (ie, stage 
I or IIA) were treated with infradiaphragmatic radiotherapy. The 
L-field or dogleg technique (  23  ,  24  ) was typically used, but in 42 
cases, the fields were limited to the para-aortic area (  23  ). Only 
eight seminoma patients received no additional treatment after 
orchiectomy. The standard target radiation dose for these stages 
was gradually reduced from 36  –  40 Gy in the early 1980s to 25.2  –
  27 Gy in the mid-1990s. Patients with advanced-stage seminomas 
(ie, stage IIB or higher) were treated with cisplatin-based chemo-
therapy, and in some patients, this was followed by radiation or 
resection of enlarged lymph nodes or by retroperitoneal lymph 
node dissection.   
    Nonseminomas.             Patients with early-stage nonseminomas (stage I 
or IIA) were, until approximately 1990, treated with a primary mod-
ified bilateral or ipsilateral template retroperitoneal lymph node 
dissection; the nerve-sparing technique was introduced in 1989. 
Retroperitoneal lymph node dissection was followed by adjuvant 
chemotherapy if lymph node metastases were present. After 1990, 
patients with stage I nonseminomas were either subjected to surveil-
lance following orchiectomy or treated with one to three cycles of 
adjuvant chemotherapy. Patients with advanced-stage nonseminomas 
(before 1990: stages IIB  –  IV; 1990 or later: stages IIA  –  IV) generally 
received at least three cycles of cisplatin-based chemotherapy, often 
combined with a formal retroperitoneal lymph node dissection or 
more limited resection of retroperitoneal lymph nodes.   
    Treatment Groups.             All participating testicular cancer survivors 
were allocated to one of six mutually exclusive groups according to 
the treatment they received following orchiectomy at the initial 
diagnosis and at relapse: 1) surveillance; 2) retroperitoneal surgery 
only; 3) radiotherapy only; 4) chemotherapy with up to four cycles 
of standard schedule cisplatin-based regimens (20 mg/m  2   per day 
for five consecutive days), with or without retroperitoneal surgery 
or radiotherapy; 5) chemotherapy with five or more cycles of stan-
dard schedule cisplatin-based regimens, with or without retroper-
itoneal surgery or radiotherapy; or 6) chemotherapy in which at 
least one of the cisplatin-based cycles was administered more than 
20 mg/m  2   per day, either because of same dose (100 mg/m 
2   per 
cycle) given over fewer days or higher dose per cycle, irrespective 
of total number of cisplatin-based cycles with or without retroper-
itoneal surgery or radiotherapy (dose-intensive chemotherapy). 
  For participating testicular cancer survivors who underwent 
ototoxicity evaluation, the three ﬁ  rst treatment groups (surveil-
lance, retroperitoneal surgery, and radiotherapy) were combined 
into one treatment group (no chemotherapy) because these treat-
ments are unlikely to have an impact on hearing.     
    Measurements 
  The 219-item mailed questionnaire included the six-item Scale for 
Chemotherapy-Induced Neurotoxicity (SCIN) (  25  ,  26  ), which 
we used to assess the relevant side effects (  Table 1  ). The partici-
pants were asked to score how troubled they were  —  not at all, a 
little, quite a bit, or very much  —  by the relevant symptoms. As in 
the EORTC QLQ C-30, the responses to the questions and their 
scaling in the SCIN were intended to reflect both the severity and 
the frequency of symptoms as experienced by the patient and, thus, 
assessed the individual’s subjective perception of the symptoms. 
Based on its psychometric properties and its brevity, the SCIN has 
been recommended (  25  ) for use as a brief screening instrument for 
chemotherapy-induced neurotoxicity. The SCIN has been used in 
other studies (  12  ,  19  ,  21  ,  26  ). For most data analyses, we used the 
ordinal scales (four categories). When the data were dichotomized jnci.oxfordjournals.org    JNCI | Articles 1685
as minor vs major symptoms, the latter were defined as those with 
responses of “quite a bit” or “very much.” 
  The questionnaire also assessed tobacco smoking habits, and 
the survivors were asked whether they had ever smoked daily, cur-
rently smoked daily, or smoked only occasionally. They were also 
asked how much they smoked or had smoked per day, how old they 
were when they started, and for how many years they smoked 
daily. On the basis of their answers, they were grouped as never 
daily smokers, former daily smokers, or current daily smokers. 
Cigarette smoking as well as tobacco consumption by pipe (n = 4) 
or cigar (n = 10) were included. 
  We considered white or cold ﬁ  ngers or hands (or toes or feet) 
as Raynaud-like phenomena because the questions about these 
symptoms did not speciﬁ  cally address the classical well-demarcated 
discoloration or the pain and numbness that characterize Raynaud 
phenomenon (  7  ). 
  Pure tone audiometry was performed as part of the outpatient 
examination in three of the ﬁ  ve participating medical centers, one 
of which performed audiometry exclusively in chemotherapy-
treated patients. Although a range of frequencies may have been 
tested, only the air conduction threshold at 4000 Hz was entered 
into the study database per the study protocol. The ability to 
detect this frequency, which represents the upper limit of the 
language communication range, is often compromised by exposure 
to cisplatin, which preferentially affects the higher frequencies 
(  27  ,  28  ). The 4000-Hz hearing thresholds for both ears were aver-
aged for each testicular cancer survivor. Published normative data 
from a large unscreened Norwegian male reference population, 
including the median and the quartiles of hearing threshold levels 
at 4000 Hz averaged for both ears for seven age groups (20  –  29, 
30  –  39, 40  –  49, 50  –  59, 60  –  69, 70  –  79, and 80  –  89 years), were used 
to create four groups of audiometric results in our study population 
(  29  ). Each testicular cancer survivor was allocated to one of the 
four groups corresponding to the respective quartile (quartiles 1  –  4) 
of the reference population according to age and averaged 4000-Hz 
hearing threshold. The group corresponding to quartile 4 had the 
most severe hearing impairment.   
    Statistical Analysis 
  Group comparisons of continuous variables were performed by 
using the Student   t   test (for comparing age at diagnoses and at 
follow-up in the study sample vs in nonassessable men) or the 
Kruskal  –  Wallis test (all comparisons of continuous data within the 
study sample). Group comparisons were performed with       2   tests 
for nominal variables or with Kruskal  –  Wallis tests for ordinal var-
iables (the symptom assessments in   Figures 1   and   2  ). The 
McNemar test was used to analyze paired data. Proportional odds 
ordinal logistic regression models were used to assess the associa-
tions between relevant factors and self-reported symptoms. All 
factors of interest were included in the models. For Raynaud-like 
phenomena and paresthesias, the treatment-related side effects 
were assessed by separate variables for receipt of retroperitoneal 
surgery (yes vs no [referent]), radiotherapy (yes vs no [referent]), 
and chemotherapy (no chemotherapy [referent], one to four cycles, 
five or more cycles, or dose intensive). The analyses for chemo-
therapy were repeated by using one to four cycles and five or more 
cycles as the referent group. The assumption of proportional odds 
  Table 1    .       Questions used to assess the relevant symptoms  *     
    Symptom assessed Question asked   
    Raynaud-like 
 phenomena,  hands
Are you troubled by white/cold 
  hands/fingers when it is cold? 
  Raynaud-like 
 phenomena,  feet
Are you troubled by white/cold 
  feet/toes when it is cold? 
  Paresthesias, hands Are you troubled by pain, tingling, or 
  numbness in your hands/fingers? 
  Paresthesias, feet Are you troubled by pain, tingling, or 
  numbness in your feet/toes? 
  Tinnitus Are you troubled by ringing in your ears? 
  Hearing impairment Are you troubled by impaired hearing?   
    *     From the Scale for Chemotherapy-Induced Neurotoxicity. The possible 
answers were 1) not at all, 2) a little, 3) quite a bit, and 4) very much.     
was checked as recommended by Harrell (  30  ), mainly by graphical 
checks of plots of partial and score residuals. We concluded that 
the assumption of proportionality was valid. Associations between 
relevant factors and audiometric results were analyzed by linear 
regression models in which the outcome variable corresponds to 
hearing impairment, in decibels (dB), at 4000 Hz (increasing 
values correspond to more severe hearing loss).                 
  To compare the side effects of vinblastine with those of etopo-
side as well as the impact of the cumulative bleomycin dose, we 
repeated the regression models for the group of men who were 
treated with chemotherapy by adding covariates for these cyto-
static agents (vinblastine vs etoposide-containing regimens and 
total cumulative bleomycin dose). 
  Spearman correlation analysis was used to assess the association 
between subjective and objective measures of hearing impairment 
and tinnitus. Men with missing data were excluded from the rele-
vant analyses. The treatment data were complete. All statistical 
tests were two-sided, and a   P   value less than .05 was considered 
statistically signiﬁ  cant.     
    Results 
    Study Population 
  Of the 1814 men who were invited to participate, 1409 were as-
sessable. Of the assessable survivors, 1402 responded to at least one 
of the six relevant symptom questions (the SCIN) and 1378 
responded to all six questions. Pure tone audiometry was con-
ducted in 755 men, seven of whom had only pure tone audiometry 
but had not responded to the relevant questions in the SCIN. The 
median time from orchiectomy to self-reported symptom assess-
ment was 10.7 years and to audiometry, 11.6 years (range for both = 
4  –  21 years). The clinical characteristics according to treatment 
group are shown in   Table 2  . Men who were included in the study 
sample did not statistically significantly differ from the 405 non-
assessable men with respect to age at diagnosis and follow-up or by 
the percentage that received surveillance, retroperitoneal surgery, 
radiotherapy, or chemotherapy after orchiectomy (data not shown). 
Among the 1409 assessable survivors, 38 reported that they had 
diabetes. None of the survivors who reported diabetes were in the 
five or more cycles or the dose-intensive chemotherapy groups; 
the frequencies of the survivors who reported diabetes in the 
remaining groups were 2.7% (surveillance), 1.3% (retroperitoneal 1686   Articles | JNCI  Vol. 101, Issue 24  |  December 16, 2009
surgery), 3.5% (radiotherapy), and 3.3% (one to four cycles) 
(  P   = .4). Data regarding cardiovascular morbidity and cardiovascu-
lar risk factors, including metabolic syndrome, were published 
previously (  31    –    33  ).           
    Symptom Scores and Assessment of Hearing 
  The severity of the reported symptoms varied statistically signifi-
cantly among the treatment groups for all side effects assessed 
(  P   < .001 for all) (  Figures 1   and   2  ). Among chemotherapy-treated 
testicular cancer survivors, the most frequently reported major 
symptoms (ie, those the participants were troubled by “quite a bit” 
or “very much”) were Raynaud-like phenomena in either the hands 
or feet (39% [95% CI = 35% to 43%]); Raynaud-like phenomena 
in these patients were more common in the hands than in the feet 
(33% vs 28%, difference = 5%, 95% CI =     1% to 10%,   P   = .006). 
However, 12% (95% CI = 7% to 19%) of survivors who were 
treated by orchiectomy alone (surveillance group) reported 
Raynaud-like phenomena in either the hands or the feet as major 
symptoms. Raynaud-like phenomena in the hands or feet were 
reported as major symptoms statistically significantly more fre-
quently by those who received five or more cycles of chemotherapy 
  Figure 1    .       Raynaud-like phenomena and paresthesias according to self-
assessed severity and treatment. Self-reported Raynaud-like phe-
nomena in the hands (  A  ) and feet (  B  ) and self-reported paresthesias in 
the hands (  C  ) and feet (  D  ) are grouped according to self-assessed symp-
tom severity for each treatment group (  P   < .001 for the comparison 
between treatment groups for each symptom [two-sided Kruskal  –  Wallis 
tests]). Symptom severity coding:   red   = troubled very much,   orange   = 
troubled quite a bit,   yellow   = troubled a little,   green   = not troubled at 
all. Surv = surveillance; RPLND = retroperitoneal lymph node dissec-
tion; RT = radiotherapy.       
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than by those who received one to four cycles of chemotherapy 
(61% vs 35%, difference = 26%, 95% CI = 11% to 40%,   P   = .001). 
These symptoms were also reported more frequently by the dose-
intensive chemotherapy group than by the group that received one 
to four cycles of chemotherapy, but the difference was not statisti-
cally significant (49% vs 35%, difference = 14%, 95% CI = 1% to 
28%,   P   = .052). 
  Paresthesias in the hands or feet were reported as major symp-
toms by 29% (95% CI = 25% to 33%) of all men who were treated 
with chemotherapy and were experienced more often in the feet 
than in the hands (22% vs 18%, difference = 4%, 95% CI =     1% 
to 9%,   P   = .04). More men in radiotherapy group and in the one 
to four chemotherapy cycles group reported paresthesias in the 
feet as major symptoms compared with men in the surveillance 
group (radiotherapy vs surveillance: 15% vs 10%, difference = 5%, 
95% CI =     2% to 10%,   P   = .16; one to four cycles vs surveillance: 
21% vs 10%, difference = 11%, 95% CI = 3% to 17%,   P   = .01). 
Paresthesias in either the hands or the feet were reported as major 
symptoms by statistically signiﬁ  cantly more men who received ﬁ  ve 
or more cycles of chemotherapy than by men who received one to 
four cycles of chemotherapy (46% vs 28%, difference = 18%, 95% jnci.oxfordjournals.org    JNCI | Articles 1687
CI = 4% to 33%,   P   = .016), whereas the frequency in the dose-
intensive group was similar to that of the one to four cycles 
(27% vs 28%, difference = 0.5%, 95% CI =     11.6% to 13.2%, 
  P   = 1.0). 
  Among all men who received chemotherapy, 21% (95% CI = 
18% to 25%) reported hearing impairment and 22% (95% CI = 19% 
to 26%) reported tinnitus as major symptoms. Tinnitus was reported 
as a major symptom by 12% of men who received no chemotherapy 
vs by 19% of those treated with one to four cycles of chemotherapy 
(difference = 7%, 95% CI = 3% to 11%,   P   = .001). Furthermore, the 
proportion of men who reported tinnitus as a major symptom in the 
dose-intensive chemotherapy group was more than twice that in 
the group that received one to four chemotherapy cycles (42% vs 
19%, difference = 23%, 95% CI = 10% to 36%,   P   < .001) and was 
reported by 28% of those who received ﬁ  ve or more cycles (not sta-
tistically signiﬁ  cantly different from one to four cycles,   P   = .17). 
  Self-reported hearing impairment as a major symptom was 
reported by 12% of men who received no chemotherapy and 
by 18% of those who received one to four chemotherapy cycles 
(difference = 6.7%, 95% CI = 2.6% to 11.2%,   P   = .001). A greater 
proportion of men who were treated with dose-intensive chemo-
therapy than with one to four chemotherapy cycles reported 
hearing impairment as a major symptom (35% vs 18%, difference = 
16.2%, 95% CI = 2.0% to 30.3%,   P   = .007). 
  We next examined the hearing thresholds at 4000 Hz, grouped 
according to age-speciﬁ  c quartiles for an unselected Norwegian 
male reference population, for the testicular cancer survivors by 
treatment group (  Figure 2, C  ). Of the men who received no che-
motherapy, 22% (95% CI = 18% to 26%) belonged to the group 
with most severe hearing loss, which corresponded to the fourth 
quartile of hearing thresholds in the reference population. Among 
chemotherapy-treated men, the proportion belonging to the 
group with most severe hearing loss increased with increasing in-
tensity of treatment (one to four cycles: 28% [95% CI = 23% to 
34%]; ﬁ  ve or more cycles: 37% [95% CI = 20% to 56%]; dose 
intensive: 69% [95% CI = 52% to 82%]; dose intensive vs one to 
four cycles,   P   < .001; ﬁ  ve or more vs one to four cycles,   P   = .4). 
  Among the 287 men who received bleomycin, etoposide, and 
cisplatin (BEP) as the initial chemotherapy regimen, 41 had 
received three complete cycles and 153 had received four cycles of 
  Figure 2    .       Hearing impairment and tinnitus according to severity and treat-
ment. Self-reported hearing impairment (  A  ) and tinnitus (  B  ) and assessed 
hearing impairment (  C  ) grouped according to severity for each treatment 
group. The severity assessments in (  A  ) and (  B  ) are those reported by the 
participants; for the severity assessment for objective hearing loss mea-
sured at 4000 Hz for each testicular cancer survivor, the hearing impair-
ment was classiﬁ  ed according quartiles of the 4000-Hz hearing thresholds 
(averaged for both ears) that were measured in a large unscreened refer-
ence population of Norwegian men. (  P   < .001 the comparison between 
treatment groups for each symptom [two-sided Kruskal  –  Wallis tests]).       
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BEP with cisplatin administered at 20 mg/m 
2   per day and no addi-
tional chemotherapy. There were no statistically signiﬁ  cant differ-
ences between men who received three BEP cycles and those who 
received four BEP cycles with respect to the percentage who 
reported any major symptoms (Raynaud-like phenomena in either 
hands or feet: 42% vs 31%,   P   = .26; paresthesias in either hands or 
feet: 24% vs 26%,   P   = 1.0; tinnitus: 12% vs 26%,   P   = .09; and 
hearing impairment: 10% vs 17%,   P   = .34). A total of 17% of men 
had hearing thresholds at 4000 Hz corresponding to the most 
severe group of hearing loss following three cycles of BEP com-
pared with 31% following four cycles of BEP (  P   = .2).   
    Association Between Self-reported and Measured Hearing 
Impairment and Tinnitus 
  There was a moderate association between subjective and objective 
(hearing threshold at 4000 Hz) measures of hearing impairment 
(Spearman correlation coefficient = .46,   P   < .001). The box plot in 
  Figure 3   illustrates the relationship between these two measures. 
The Spearman correlation coefficient for the association between 
self-reported hearing impairment and tinnitus was .49 (  P   < .001).           
    Prediction of Side Effects 
  We used proportional ordinal logistic regression models to assess 
associations between the reported symptoms and cancer treatment 
and other factors of interest. Compared with no chemotherapy, all 
three chemotherapy groups had statistically significantly higher 
odds for increasing severity of all assessed self-reported symptoms 
(  Tables 3   and   4  ) and, in a linear regression model, statistically 
significantly inferior audiometry results (except for five or more 
chemotherapy cycles,   P   = .06) (  Table 5  ). There were no statisti-
cally significant associations between the severity of any of the 
self-reported or objectively measured symptoms and the length of 
follow-up. High education level was associated with statistically 
significantly lower odds for all symptoms compared with low edu-
cation level, whereas marital status was statistically significantly 
associated only with Raynaud-like phenomena.                         
    Raynaud-Like Phenomena and Paresthesias.             The odds ratios 
(ORs) for Raynaud-like phenomena and paresthesias among men 
who received one to four cycles of chemotherapy compared with 
those who received no chemotherapy were 2.0  –  2.9 (  Table 3  ). For 
the men who received five or more cycles of chemotherapy, the odds 
ratios for paresthesias in feet and hands were 3.1 (95% CI = 1.7 to 
5.7) and 3.9 (95% CI = 2.1 to 7.3), respectively, and for Raynaud-like 
phenomena, 6.3 (95% CI = 3.4 to 11.8) and 8.0 (95% CI = 4.4 to 
14.7), respectively (  Table 3  ), all of which, with the exception of the 
odds ratio for paresthesias in feet, implied statistically significantly 
more severe symptoms for these men compared with men who 
received one to four cycles of chemotherapy (paresthesias in hands: 
  P   = .03; Raynaud-like phenomena in feet:   P   = .001; Raynaud-like 
phenomena in hands:   P   = .001). The odds regarding Raynaud-like 
phenomena were also statistically significantly higher for the dose-
intensive chemotherapy group than for the one to four chemo-
therapy cycles group (  P   = .002 [hands],   P   = .02 [feet]). 
  Testicular cancer survivors who were treated with radiotherapy 
had statistically signiﬁ  cantly higher odds of self-reported paresthe-
sias in feet than those who were not treated with radiotherapy (OR 
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    Figure 3    .       Relationship between reported and assessed hearing impair-
ment. Box plot of impaired hearing in decibels (dB) measured by pure 
tone audiometry at 4000 Hz in relation to reported hearing impairment 
for 746 testicular cancer survivors for whom both assessments were 
available. The   dark line   within the box is the median value, the   lower 
and upper boundaries   of each box represent the 25th and 75th percen-
tiles, respectively, and the   whiskers   represent the minimum and max-
imum values.         
= 1.5, 95% CI = 1.01 to 2.1,   P   = .04) (  Table 3  ). The severity of 
Raynaud-like phenomena and paresthesias in hands and feet 
increased with increasing age (ORs of 1.2  –  1.4 per decade). 
Compared with never daily smoking, current daily smoking was 
statistically signiﬁ  cantly associated with Raynaud-like phenomena 
and paresthesias (ORs of 1.5  –  2.2) (  Table 3  ). Paresthesias in feet 
were also statistically signiﬁ   cantly associated with former daily 
smoking (OR = 1.8, 95% CI = 1.4 to 2.5).   
    Hearing Impairment and Tinnitus.             Men who received one to 
four cycles of cisplatin-based chemotherapy were statistically sig-
nificantly more inclined to report increased severity of hearing 
impairment (OR = 1.5, 95% CI = 1.2 to 2.0) and tinnitus (OR = 
1.8, 95% CI = 1.4 to 2.4) than those who did not receive chemo-
therapy (  Table 4  ). The predicted hearing threshold was 3.2 dB 
higher (95% CI = 0.4 to 6.1 dB,   P   = .02) in the one to four cycles 
group compared with the no chemotherapy group (  Table 5  ). Men 
who received five or more cycles of chemotherapy also had more 
severe hearing impairment (OR = 3.8, 95% CI =2.1 to 6.8,   P   < 
.001) and tinnitus (OR = 3.4, 95% CI = 1.9 to 5.9,   P   < .001) com-
pared with men who received no chemotherapy, with a predicted 
hearing threshold of 6.3 dB (95% CI = 0.3 to 12.9 dB), and com-
pared with men who received one to four cycles of chemotherapy 
(  P   = .004 and   P   = .04, respectively). Ototoxicity was most pro-
nounced among men who had received dose-intensive chemo-
therapy compared with those who received no chemotherapy 
(reported hearing impairment: OR = 5.3, 95% CI = 3.0 to 9.2; 
tinnitus: OR = 7.1, 95% CI = 4.1 to 12.4). The elevated hearing 1690   Articles | JNCI  Vol. 101, Issue 24  |  December 16, 2009
threshold among men who had received dose-intensive chemo-
therapy vs those who received no chemotherapy  —  20.3 dB (95% 
CI = 14.1 to 26.6 dB)  —  was comparable to that for a 20-year 
increase in age (  Table 5  ). All ototoxicity measures were statistically 
significantly more severe in the dose-intensive chemotherapy 
group than in the one to four chemotherapy cycles group (  P   < 
.001). Statistically significantly higher hearing thresholds (  P   = 
.002) and more severe tinnitus (  P   = .048) were also found among 
  Table 3    .       Odds ratios (ORs) and 95% confidence intervals (CIs) for increasing severity of self-reported Raynaud-like phenomena and 
paresthesias in hands and feet from proportional odds ordinal logistic regression models  *     
    Variable
Raynaud-like phenomena    Paresthesias     
  Hands Feet Hands Feet 
  OR (95% CI)   P  OR (95% CI)   P  OR (95% CI)   P  OR (95% CI)   P     
    Age at follow-up    †    1.2 (1.1 to 1.4) .002 1.3 (1.1 to 1.4) <.001 1.2 (1.1 to 1.4) .001 1.4 (1.2 to 1.6) <.001 
  Length of follow-up    ‡    1.01 (0.98 to 1.04) .68 1.0 (0.97 to 1.03) .90 1.01 (0.98 to 1.04) .47 1.01 (0.98 to 1.04) .73 
  Chemotherapy  <.001   <.001  <.001  <.001 
         No 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         1  –  4 cycles 2.9 (2.2 to 3.9) <.001 2.4 (1.8 to 3.3) <.001 2.0 (1.5 to 2.7) <.001 2.2 (1.7 to 3.0) <.001 
           ≥  5 cycles 8.0 (4.4 to 14.7) <.001 6.3 (3.4 to 11.8) <.001 3.9 (2.1 to 7.3) <.001 3.1 (1.7 to 5.7) <.001 
         Dose intensive 5.7 (3.2 to 9.9) <.001 4.7 (2.6 to 8.3) <.001 2.3 (1.3 to 4.1) .007 3.8 (2.1 to 6.9) <.001 
  Radiotherapy  .10   .10  .22  .04 
         No 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         Yes 1.3 (0.95 to 1.9)   1.4 (0.95 to 1.9)   1.3 (0.9 to 1.8)   1.5 (1.01 to 2.1)  
  RPLND  .20   .52  .15  .27 
         No 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         Yes 1.3 (0.9 to 1.8)   1.1 (0.8 to 1.6)   1.3 (.9 to 1.9)   1.2 (0.9 to 1.7)  
  Cigarette smoking  <.001   <.001  <.001  <.001 
         Never daily 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         Former daily 1.1 (0.8 to 1.5) .57 0.9 (0.7 to 1.3) .71 1.1 (0.8 to 1.6) .44 1.8 (1.4 to 2.5) <.001 
         Current daily 1.7 (1.3 to 2.2) <.001 1.5 (1.2 to 2.0) .002 1.9 (1.4 to 2.5) <.001 2.2 (1.6 to 2.8) <.001 
  Educational level  .03   .01   <.001  .004 
         Primary, middle, or high school 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         College or university 0.8 (0.6 to 0.98)   0.7 (0.6 to 0.9)   0.6 (0.4 to 0.7)   0.7 (0.6 to 0.9)  
  Marital status  .04   .003  .81   .31 
         Unmarried or living alone 1.00 (referent)   1.00 (referent)   1.00 (referent)   1.00 (referent)  
         Married or cohabitating 0.8 (0.6 to 0.98)   0.7 (0.5 to 0.9)   1.0 (.7 to 1.3)   0.9 (0.7 to 1.4)    
    *     RPLND = retroperitoneal lymph node dissection.   
      †       Per 10-year increase.   
      ‡       Per 1-year increase.     
  Table 4    .       Odds ratios (ORs) and 95% confidence intervals (CIs) for increasing severity of self-reported hearing impairment and tinnitus 
from proportional odds ordinal logistic regression models   
    Variable
Hearing impairment    Tinnitus     
  OR (95% CI)   P  OR (95% CI)   P     
    Age at follow-up  *  1.7 (1.5 to 1.9) <.001 1.3 (1.2 to 1.5) <.001 
  Length of follow-up    †    1.0 (.96 to 1.01) .35 1.0 (.95 to 1.01) .13 
  Chemotherapy  <.001  <.001 
         No 1.00 (referent)   1.00 (referent)  
         1  –  4 cycles 1.5 (1.2 to 2.0) <.001 1.8 (1.4 to 2.4) <.001 
           ≥  5 cycles 3.8 (2.1 to 6.8) <.001 3.4 (1.9 to 5.9) <.001 
         Dose intensive 5.3 (3.0 to 9.2) <.001 7.1 (4.1 to 12.4) <.001 
  Cigarette smoking  .053  .21 
         Never daily 1.00 (referent)   1.00 (referent)  
         Former daily 1.2 (.09 to 1.6) .17 1.2 (0.9 to 1.7) .16 
         Current daily 1.4 (1.1 to 1.8) .02 1.3 (1.0 to 1.7) .10 
  Educational level  <.001  <.001 
         Primary, middle, or high school 1.00 (referent)   1.00 (referent)  
         College or university 0.5 (0.4 to 0.7)   0.6 (0.5 to 0.8)  
  Marital status  .66  .62 
         Unmarried or living alone 1.00 (referent)   1.00 (referent)  
         Married or cohabitating 1.1 (.8 to 1.4)   0.9 (0.7 to 1.2)    
    *     Per 10-year increase.   
      †       Per 1-year increase.     jnci.oxfordjournals.org    JNCI | Articles 1691
men who received dose-intensive chemotherapy compared with 
men who received five or more chemotherapy cycles. 
  Compared with never daily smokers, daily smokers had statisti-
cally signiﬁ   cant more severe reported and measured impaired 
hearing (  P =   .02 for both). However, the overall   P   values for the 
associations between smoking and self-reported as well as mea-
sured impaired hearing was not statistically signiﬁ  cant (  P   = .053 
and   P   = .058, respectively) (  Tables 4   and   5  ).   
    Influence of Type of Cytostatic Drugs.             There were no statisti-
cally significant differences in the self-reported severity of any of 
the assessed symptoms or audiometric results between men treated 
with chemotherapy regimens that contained vinblastine and those 
treated with chemotherapy regimens that contained etoposide 
(data not shown). The total cumulative bleomycin dose was not 
statistically significantly associated with self-reported Raynaud-
like phenomena or paresthesias (data not shown).       
    Discussion 
  Our results show that at 4  –  21 years after the initiation of treatment 
for testicular cancer, compared with men not treated with chemo-
therapy, those who had received any chemotherapy had statisti-
cally significantly higher odds for increasing severity of all assessed 
symptoms and, except for those who received five or more cycles, 
worse audiometric results. Compared with men who had received 
one to four cycles of chemotherapy, those who had received five or 
more cycles or dose-intensive chemotherapy were statistically sig-
nificantly more troubled by most of the assessed symptoms. 
Hearing impairment and tinnitus were substantial in the dose- 
intensive group, whereas Raynaud-like phenomena and paresthe-
sias were most common among men treated with five or more 
chemotherapy cycles. Radiotherapy was associated with paresthe-
sias in feet. Finally, compared with never daily smoking, current 
daily smoking was statistically significant associated with Raynaud-
like phenomena, paresthesias, and self-reported and measured 
hearing impairment. 
  A strength of this study is the large sample size of unselected 
testicular cancer survivors for whom we had detailed treatment 
information, which allowed us to compare the impact of various 
treatments as well as the dose intensity of cisplatin within a single 
cohort. Comparison between treatment groups within one cohort 
is particularly suitable for survivorship research, given that com-
parisons between studies may be difﬁ   cult because of different 
methods of assessment and scoring systems, time to follow-up, and 
differences regarding treatment (  3  ). In addition, the high partici-
pation rate increases the validity of our ﬁ  ndings, and the long-term 
follow-up is, to our knowledge, quite unique. 
  The main limitation of this study is that it is largely based on 
self-reported symptoms, and the reported toxic effects were, with 
the exception of hearing threshold measurements, not objectively 
conﬁ  rmed. However, the level of self-reported symptoms probably 
best reﬂ  ects the impact of the toxic effects on a cancer survivor’s 
well-being during daily life. Moreover, previous studies have 
shown that the prevalence of these toxic effects is even higher 
when objectively tested (  3  ,  10  ,  11  ). There are also some limitations 
concerning the SCIN. As a brief screening instrument, it did not 
  Table 5    .       Factors associated with hearing impairment at 4000 Hz in 
a linear regression model  *     
    Factor
Regression coefficient    †     
(95% CI)   P     
    Age at follow-up    †    10.5 (9.2 to 11.9) <.001 
  Length of follow-up .08 (    0.2 to .4) .64 
  Chemotherapy  <.001 
         No 0 (referent)  
           ≤  4 cycles 3.2 (0.4 to 6.1) .02 
           ≥  5 cycles 6.3 (    0.3 to 13.0) .06 
         Dose intensive 20.3 (14.1 to 26.6) <.001 
  Cigarette smoking  .058 
         Never daily 0 (referent)  
         Former daily 1.5 (    1.8 to 4.8) .38 
         Current daily 3.7 (0.6 to 6.8) .02 
  Educational level  .001 
         Primary, middle, or high school 0 (referent)  
         College or university     4.6 (    7.4 to     2.0)  
  Marital status  .092 
         Unmarried or living alone 0 (referent)  
         Married or cohabitating     2.7 (    5.9 to 0.4)    
    *     CI = confidence interval.   
      †       In decibels. Increasing values correspond to more severe hearing loss.   
      ‡       Per 10-year increase.     
address each symptom in detail, such as all classical signs of 
Raynaud phenomena (  7  ). Therefore, some of the men who were 
classiﬁ  ed as having Raynaud-like phenomena may include men 
who had cold-induced pallor but not all of the classical signs of 
Raynaud phenomena (  7  ). Likewise, we cannot rule out that some 
men with reported paresthesias may have had pain in their hands 
or feet because of other conditions. Because this was a cross-
sectional study, we do not have information about the existence of 
symptoms before diagnoses or whether they changed over time. 
Unequal access to health care was not likely to be a confounding 
factor in this study because both the primary health-care system 
and the follow-up routines at hospitals are well established and 
evenly distributed in Norway. 
  Raynaud-like phenomena were the most frequently reported 
major symptoms among chemotherapy-treated testicular cancer 
survivors in our study. Although Raynaud phenomenon is a 
common disorder in the general population, its prevalence varies 
by sex and climate zone (  7  ). The 12% prevalence of major 
Raynaud-like phenomena in the surveillance group is similar to the 
male prevalence of Raynaud phenomenon in an area with mean 
January temperature of     0.4°C (  34  ), which is somewhat warmer 
than the mean January temperature in most parts of Norway (  35  ). 
Although the frequency of reported major Raynaud-like phe-
nomena among all chemotherapy-treated testicular cancer survi-
vors (39%) is similar to the typically reported long-term rates of 
Raynaud phenomena of 25% –  45% ( 3    –    6  ,  10  ,  15  ,  36  ,  37  ), the frequency 
we observed among men who received ﬁ  ve or more chemotherapy 
cycles  —  61%  —  is somewhat higher than the 44% rate reported by 
Hansen and Olsen (  10  ) in germ cell cancer patients treated with 
six cycles of cisplatin, vinblastine, and bleomycin. Interestingly, 
they found that these patients had an exaggerated response to cold, 
even those without ﬁ  nger symptoms. 1692   Articles | JNCI  Vol. 101, Issue 24  |  December 16, 2009
  We found statistically signiﬁ  cantly higher odds for increasing 
severity of Raynaud-like phenomena for men who received ﬁ  ve or 
more chemotherapy cycles or dose-intensive chemotherapy than 
for men who received one to four cycles of chemotherapy. 
Although previous smaller studies did not detect any association 
between Raynaud-like phenomena and the cumulative cisplatin 
dose or the number of chemotherapy cycles (  5  ,  36    –    38  ), an associa-
tion with cisplatin is likely because the incidence of Raynaud-like 
phenomena following chemotherapy for testicular cancer seemed 
to increase following the introduction of cisplatin (  9  ). We found 
no association between Raynaud-like phenomena and bleomycin 
dose, in contrast to the study by Berger et al. (  5  ). However, this 
lack of an association in our study is not inconsistent with bleomy-
cin being the principal cause of Raynaud phenomenon (  39  ) because 
all but 17 of our patients received bleomycin, mostly within a 
limited dose range (median dose was 300    000 IU, and 77% of 
patients received between 240    000 and 360    000 IU). 
  The neurotoxic effects of testicular cancer treatment are mainly 
cisplatin-induced sensory neuropathies that are chieﬂ  y caused by 
toxic effects on the dorsal root ganglia neurons; however, other 
mechanisms may be involved (  40    –    42  ). The higher prevalence of 
reported major paresthesias following ﬁ  ve or more cycles than 
following one to four cycles in this study is consistent with pre-
vious data suggesting that both the incidence and the severity of 
paresthesias are mainly determined by the cumulative cisplatin 
dose (  3  ,  41  ). Persisting paresthesias have previously been reported 
in 14%  –  43% of men following cisplatin-based chemotherapy for 
testicular cancer (  3  ,  4  ,  11  ,  13  ,  15  ,  37  ,  43  ,  44  ). This wide range is likely 
to be inﬂ   uenced by several factors, including the length of 
follow-up, chemotherapy regimen, and dose. 
  We found that radiotherapy was associated with paresthesias in 
the feet. Although neurological side effects following radiotherapy 
of the para-aortic and iliac areas are considered to be rare, postir-
radiation lower motor neuron syndrome with paresis as well 
as transient sensory symptoms have been described in testicular 
cancer patients treated with radiotherapy (  24  ). 
  We observed that ototoxicity increased with treatment intensity 
and was particularly pronounced among men who had received 
dose-intensive chemotherapy. Chemotherapy-induced ototoxicity 
is mainly ascribed to cisplatin, which causes loss of outer hair cells 
in the organ of Corti, leading to tinnitus and hearing impairment 
(  45  ,  46  ). Although cisplatin-induced hearing loss initially involves 
the higher frequencies, it can eventually affect a broader range of 
frequencies (  47  ,  48  ). Both the total and the peak plasma dose of 
cisplatin are considered relevant measures associated with the oto-
toxic effects of this drug (  49  ). 
  We found that ototoxicity was substantial in men who had 
received dose-intensive chemotherapy. However, there was also a 
statistically signiﬁ  cant elevation of the odds of ototoxic symptoms 
with increasing number of chemotherapy cycles (none, one to four, 
and ﬁ  ve or more cycles), as well as   statistically signiﬁ  cantly greater   
predicted hearing impairment in those who had received one to 
four cycles and dose-intensive chemotherapy compared with no 
chemotherapy. Bokemeyer et al. (  28  ) reported persisting ototoxic 
symptoms in 17 (20%) of the 86 testicular cancer patients treated 
with cisplatin-based chemotherapy and that the cumulative cis-
platin dose was a highly statistically signiﬁ  cant predictor of ototox-
icity. In that study, 12% of the patients received regimens that 
included high-dose cisplatin. An increased risk of ototoxicity has 
been described previously for a 3-day BEP regimen (etoposide 
administered for more than 3 days and cisplatin for more than 
2 days with 50 mg/m  2   cisplatin on days 1 and 2) vs the 5-day BEP 
regimen (20 mg/m  2   cisplatin on days 1  –  5), particularly if four cy-
cles was administered (  12  ). Such an increased risk should also be 
considered if three cycles are planned (  12  ). 
  The proportions of men in the three chemotherapy groups who 
reported major hearing impairment (18%  –  35%) and, to some 
degree, tinnitus (19%  –  42%), were somewhat higher than those 
previously reported for persisting ototoxic symptoms (  4  ,  15  ,  28  ,  50  ). 
Variation in the frequency of these symptoms may reﬂ  ect differ-
ences in age at follow-up among these studies. 
  In this study, the testicular cancer survivors  ’   audiometric results 
were categorized into four groups according to age-speciﬁ  c quar-
tiles of a large Norwegian reference population published in 2005 
(  29  ). We found that the proportion of men in the group corre-
sponding to quartile 4 (most severe hearing loss) was 28% (one to 
four cycles), 37% (ﬁ  ve or more cycles), and 69% (dose intensive) 
in the three chemotherapy groups. The predicted hearing impair-
ment in decibels in these three groups was 3.2, 6.3, and 20.3, re-
spectively. In previous studies of men treated with chemotherapy 
for testicular cancer that included audiometry (  11  ,  15  ,  28  ,  51  ), 
hearing threshold alterations were reported in 28%  –  77% of cases. 
Comparing our results of measured hearing impairment with the 
results of these previous studies is not feasible because the criteria 
for hearing threshold alterations used in these studies varied. The 
hearing threshold before treatment was not known for the men in 
this study. However, Hansen et al. (  11  ), who compared the audi-
ometry results of patients before and after six cycles of cisplatin, 
vinblastine, and bleomycin, found that treatment induced high-
frequency hearing loss in 39% of the patients. 
  We found no statistically signiﬁ  cant differences in any of the 
assessed symptoms, analyzed by regression models, between men 
exposed to etoposide (as in BEP) and those exposed to vinblastine 
(as in CVB). Others have also found that the long-term effects of 
the two regimens are similar, although the CVB regimen has been 
associated with more acute neurotoxicity and Raynaud phenomena 
compared with BEP (  3  ,  5  ,  52  ). We have not assessed the impact of 
vincristine, which was administered to 40 of the men included in 
this study. However, neurotoxic symptoms were reported to 
be transient in the majority of patients following treatment with 
vincristine-containing regimens in previous studies (  3  ,  21  ,  42  ), and 
the prevalence of persisting symptoms in those studies was less 
than that reported by men in this study who received one to four 
cycles of chemotherapy. 
  There was no statistically signiﬁ  cant association between the 
length of follow-up and the severity of any of the self-reported 
symptoms or audiometric results, as analyzed by proportional odds 
and linear regression models. This ﬁ  nding may suggest that the 
symptoms had stabilized after a follow-up of 4  –  21 years. It is well 
recognized that improvements in symptoms such as tinnitus, par-
esthesias, and Raynaud-like phenomena may occur during the ﬁ  rst 
months or year following treatment for testicular cancer (  12  ), but 
data on long-term changes in symptoms are sparse. In a small lon-
gitudinal study of men treated for testicular cancer, a decline in the jnci.oxfordjournals.org    JNCI | Articles 1693
number of men who reported paresthesias followed by normaliza-
tion of vibration perception was observed, even many years after 
treatment (  11  ,  43  ). 
  We found that compared with never daily smoking, current 
daily smoking was statistically signiﬁ  cant associated with Raynaud-
like phenomena and paresthesias as well as with self-reported and 
measured impaired hearing. Paresthesias in feet were also statisti-
cally signiﬁ  cantly associated with former daily smoking compared 
with never daily smoking. An increased risk of Raynaud phenom-
enon in male smokers has been reported in a population-based 
cohort (  53  ); however, studies in the general population (  54  ) and 
among testicular cancer patients (  5  ,  9  ,  55  ) have shown conﬂ  icting 
results. To our knowledge, this is the ﬁ  rst study to describe an 
association between smoking and peripheral neuropathy or 
impaired hearing following cancer treatment. However, associa-
tions have been described between smoking and neuropathies re-
lated to speciﬁ   c diseases (ie, diabetes and chronic obstructive 
pulmonary disease) (  56    –    59  ) or hearing loss (  60    –    64  ). Neurotoxic 
constituents of tobacco have been proposed to play a role in these 
associations with neuropathies, although an indirect effect of to-
bacco through the vasculature supplying the nerves, chronic hyp-
oxemia, and other effects have also been discussed (  56  ,  59  ,  60  ). 
  We were not able to assess any associations between the assessed 
symptoms and alcohol consumption because of insufﬁ  cient data in 
our series. Nerves that have been previously damaged by alcohol 
exposure, diabetes mellitus, or inherited neuropathy seem to be 
predisposed to develop chemotherapy-induced neuropathy (  42  ). 
However, in this study, there were no men with diabetes in the 
chemotherapy groups that were the most affected by the assessed 
symptoms (ie, ﬁ  ve or more cycles or dose-intensive groups). 
  An important issue is whether the side effects of testicular can-
cer treatments can be prevented or the symptoms ameliorated. A 
major aim in the treatment of testicular cancer is to minimize toxic 
effects without compromising the high cure rate. Our data favor 
the use of chemotherapy regimens that contain 20 mg/m  2   cisplatin 
per day to limit ototoxicity. We found no statistically signiﬁ  cant 
difference between three and four cycles of BEP with respect to 
any of the assessed symptoms. However, as illustrated by the com-
parison of the one to four cycles group with the ﬁ  ve or more cycles 
group, the total chemotherapy treatment burden is highly relevant 
with respect to side effects. Chemotherapy for testicular cancer 
should thus be chosen wisely according to guidelines and evidence-
based medicine and should not be administered for longer dura-
tion than needed based on data from phase III trials (  65    –    67  ). For 
men diagnosed with stage I nonseminomas, the recommendations 
regarding adjuvant treatment vary according to country and risk 
factors, with surveillance or one to two cycles of BEP being the 
most commonly used options. The total treatment burden, in-
cluding potential salvage treatment, and possible side effects are 
important issues in these treatment decisions, as discussed by 
Tandstad et al. (  68  ) in the context of a study that included 745 
unselected men with stage I nonseminomas who were treated 
within the SWENOTECA collaboration. 
  To our knowledge, no drug is yet available that reliably pre-
vents chemotherapy-induced neuropathy or effectively improves 
the symptoms of established neuropathies (  42  ,  69  ,  70  ). Medications 
such as calcium channel antagonists can be tried to relieve symp-
toms of Raynaud phenomena, although such medications are 
probably less effective in treating Raynaud phenomena in patients 
after chemotherapy than in individuals with no underlying cause 
(  7  ). Use of such medications was not assessed in this study. 
Preventing exposure to additional contributing factors, such as 
avoiding cold exposure of the digits in men with Raynaud phe-
nomena, may be of beneﬁ  t. When applicable, advice regarding 
lifestyle interventions, including cessation of smoking, should be 
given to testicular cancer survivors who might have an increased 
risk of cardiovascular morbidity. We found associations between 
smoking and several of the assessed symptoms in this study, which 
may imply yet another reason to motivate patients to quit smoking. 
In the future, individualized treatment of testicular cancer patients 
according to the functional polymorphisms they may harbor in 
genes that encode drug-detoxifying enzymes may be feasible 
(  71  ,  72  ). 
  In conclusion, testicular cancer survivors who were treated 
with up to four cycles of cisplatin-based chemotherapy were 
troubled more often by neuro- and ototoxic side effects and by 
Raynaud-like phenomena several years after treatment compared 
with those not treated with chemotherapy. Men who received 
more intensive chemotherapy were troubled even more by most 
of the assessed symptoms compared with those who received up 
to four cycles.   
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